February 22, 2021
Related Post
- AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants - May 4th, 2021
- Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19 - May 4th, 2021
- CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021 - May 4th, 2021
- Sanofi: Information concerning the total number of voting rights and shares - March 2021 - May 4th, 2021
- Number of voting rights as of April 30, 2021 - May 4th, 2021
- Opiant Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021 - May 4th, 2021
- iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors - May 4th, 2021
- Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021™... - May 4th, 2021
- Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021 - May 4th, 2021
- Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 4th, 2021
- Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives - May 4th, 2021
- Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021 - May 4th, 2021
- Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium - May 4th, 2021
- Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial... - May 4th, 2021
- Tower One Announces Filing of its Q4 and Year 2020 Annual Report - May 4th, 2021
- ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer - May 4th, 2021
- Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update - May 4th, 2021
- PLx Pharma Inc. to Discuss 2021 First Quarter Financial Results on May 14, 2021 Conference Call and Provide Business Update - May 4th, 2021
- Teligent, Inc. Announces 2020 Year-End Earnings Report and Provides Business Update - May 4th, 2021
- New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses - May 4th, 2021
- Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for... - May 2nd, 2021
- 4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference - May 2nd, 2021
- Kraig Biocraft Laboratories Celebrates Arbor Day by Funding Planting of more than 100,000 Mulberry Trees - May 2nd, 2021
- Galapagos creates new subscription right plans - May 2nd, 2021
- PCI Biotech: First US patient enrolled in the fimaChem pivotal RELEASE study - May 2nd, 2021
- ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021 - May 2nd, 2021
- Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and... - May 2nd, 2021
- Blueberries Medical Reports 2020 Financial Results - May 2nd, 2021
- AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020 - May 2nd, 2021
- ECMOHO Announces Fourth Quarter Unaudited Financial Results and Fiscal Year 2020 Audited Financial Results - May 2nd, 2021
- Eve & Co Announces Financial Results for the Year Ended December 31, 2020 - May 2nd, 2021
- Shattuck Labs Announces Participation in Upcoming May Conferences - May 2nd, 2021
- Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May - May 2nd, 2021
- Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases... - May 2nd, 2021
- Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept - May 2nd, 2021
- Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in... - May 2nd, 2021
- Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage... - May 2nd, 2021
- Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in... - May 2nd, 2021
- Approval of dividend - April 30th, 2021
- Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer - April 30th, 2021
- Acerus Announces Closing of US$15 Million Secured Loan Facility - April 30th, 2021
- Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy - April 30th, 2021
- Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021 - April 30th, 2021
- AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss) - April 30th, 2021
- BeyondSpring Files 2020 Annual Report on Form 20-F - April 30th, 2021
- Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th - April 30th, 2021
- SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in... - April 30th, 2021
- Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors - April 30th, 2021
- BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary... - April 30th, 2021
- Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE - April 30th, 2021
- Rafarma and Haifa Technopark Enter Talks for Joint Venture - April 30th, 2021
- Polydex Pharmaceuticals Issues Year End Financial Results - April 30th, 2021
- Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women... - April 30th, 2021
- Axiom Presents “Unified Platforms: Benefits and considerations when running global studies” at Outsourcing in Clinical Trials Europe 2021 - April 30th, 2021
- Annual General Meeting of April 30, 2021 - April 30th, 2021
- Santhera Completes Capital Increases for Financing Arrangements - April 30th, 2021
- 22nd Century Group Welcomes Ban on Menthol Cigarettes and Anticipates Further Standards as FDA Commissioner Reports Nicotine Cap on Combustibles... - April 30th, 2021
- AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities - April 30th, 2021
- 4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from... - April 28th, 2021
- Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 - April 28th, 2021
- Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting - April 28th, 2021
- New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of... - April 28th, 2021
- Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT - April 28th, 2021
- Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021 - April 28th, 2021
- Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting - April 28th, 2021
- COMPASS Pathways launches proposed public offering - April 28th, 2021
- AnPac Bio to Report Fiscal Year 2020 Financial Results on Friday, April 30, 2021 - April 28th, 2021
- Supernus to Host First Quarter 2021 Financial Results Conference Call - April 28th, 2021
- CMS Proposes Additional Payment for Shockwave’s Coronary IVL in Hospital Inpatient Cases - April 28th, 2021
- US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative... - April 28th, 2021
- Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV - April 28th, 2021
- argenx Management to Present at Upcoming Virtual Investor Conferences - April 28th, 2021
- Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy - April 28th, 2021
- Innate Pharma Files its 2020 Universal Registration Document (Document d'Enregistrement Universel) and 2020 Annual Report on Form 20-F - April 28th, 2021
- Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people - April 28th, 2021
- Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER - April 28th, 2021
- Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic - April 28th, 2021
- ("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered... - April 28th, 2021
- Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer - April 26th, 2021
- Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies - April 26th, 2021
